Displacement of Valproic Acid and Carbamazepine from Protein Binding in Normal and Uremic Sera by Tolmetin, Ibuprofen, and Naproxen: Presence of Inhibitor in Uremic Serum That Blocks Valproic Acid-Naproxen Interactions

Therapeutic Drug Monitoring

Volumn 18, Issue 3, 1996, Pages 284-287

  Dasgupta, Amitava ^a,b   Volk, April ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

Carbamazepine; Ibuprofen; Naproxen; Tolmetin; Uremia; Valproic acid

Indexed keywords

CARBAMAZEPINE; IBUPROFEN; NAPROXEN; TOLMETIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EPILEPSY; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; UREMIA;

BINDING, COMPETITIVE; BLOOD PROTEINS; CARBAMAZEPINE; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HUMANS; IBUPROFEN; NAPROXEN; PROTEIN BINDING; REFERENCE VALUES; TOLMETIN; UREMIA; VALPROIC ACID;

EID: 0029893728     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199606000-00011     Document Type: Article

References (14)

1. Bruni J, Albright P. Valproic acid therapy for complex partial seizure: its efficacy and toxic effects. Arch Neurol 1983; 40:135-7.
2. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a five year follow up study on 100 children. Acta Neurol Scand 1982;65:504-23.
3. Klotz U, Antonin KH. Pharmacokinetics and bio-availability of sodium valproate. Clin Pharmacol Ther 1977;21:736-43.
4. Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anti-epileptics and free fatty acids. Epilepsia 1979;20: 85-90.
5. Lawless L, DeMonaco H, Muindo L. Protein binding of carbamazepine in epileptic patients. Neurology 1982;32: 415-18.
6. Mackichan L, DeMonaco H, Muido L. Salivary concentration and plasma protein binding of carbamazepine-10,11 epoxide in epileptic patients. Br J Clin Pharmacol 1981;12:31-7.
7. Schobben F, Vree TB, Vander Kleijn E. Pharmacokinetics, metabolism, and distribution of 2-n-propylpentanoate (sodium valproate) and the influence of salicylate co-medication. In: Meinhardi H, Rowan AT, eds. Advances in epileptology. Amsterdam: Sweets and Zeitlinger, 1978:271-7.
8. Dasgupta A, Thompson WC. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera. Ther Drug Monit 1995;17:199-202.
9. Perucca E. Free level monitoring of antiepileptic drugs clinical usefulness and case studies. Clin Pharmacokinet 1984; 9(suppl):71-8.
10. Takeda A, Gotto H, Amano Y, Kukino K. A study on serum and CSF levels of sodium valproate, a new anti-epileptic drug. Bruin Dev 1976;8:401-8.
11. Bruni J, Wang LH, Marbury TC, Lee CS, Wilder BJ. Protein binding of valproic acid in uremic patients. Neurology 1980;30:557-9.
12. Sjoholm I, Kober A, Odar-Cederlof I, Borga A. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976;25: 1205-13.
13. Grimaldi R, Lecchini S, Crema F, Perucca E. In vivo plasma protein binding interaction between valproic acid and naproxen. Eur J Drug Metab Pharmacokinet 1984;9:359-63.
14. Dasgupta A, Jacques M. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared to normal sera: role of uremic compounds. Am J Clin Pathol 1994;101:349-53.